Expert Review of Neurotherapeutics最新文献_第3页

Predicting and improving outcome in severe pediatric traumatic brain injury. 预测和改善严重小儿脑外伤的预后。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-10-01 Epub Date: 2024-08-14 DOI: 10.1080/14737175.2024.2389921

Mathilde Chevignard, Hugo Câmara-Costa, Georges Dellatolas

{"title":"Predicting and improving outcome in severe pediatric traumatic brain injury.","authors":"Mathilde Chevignard, Hugo Câmara-Costa, Georges Dellatolas","doi":"10.1080/14737175.2024.2389921","DOIUrl":"10.1080/14737175.2024.2389921","url":null,"abstract":"Introduction: Severe pediatric traumatic brain injury (spTBI), including abusive head trauma (AHT) in young children, is a major public health problem. Long-term consequences of spTBI include a large variety of physical, neurological, biological, cognitive, behavioral and social deficits and impairments.Areas covered: The present narrative review summarizes studies and reviews published from January 2019 to February 2024 on spTBI. Significant papers published before 2019 were also included. The article gives coverage to the causes of spTBI, its epidemiology and fatality rates; disparities, inequalities, and socioeconomic factors; critical care; outcomes; and interventions.Expert opinion: There are disparities between countries and according to socio-economic factors regarding causes, treatments and outcomes of spTBI. AHT has an overall poor outcome. Adherence to critical care guidelines is imperfect and the evidence-base of guidelines needs further investigations. Neuroimaging and biomarker predictors of outcomes is a rapidly evolving domain. Long-term cognitive, behavioral and psychosocial difficulties are the most prevalent and disabling. Their investigation should make a clear distinction between objective (clinical examination, cognitive tests, facts) and subjective measures (estimations using patient- and proxy-reported questionnaires), considering possible common source bias in reported difficulties. Family/caregiver-focused interventions, ecological approaches, and use of technology in delivery of interventions are recommended to improve long-term difficulties after spTBI.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"963-983"},"PeriodicalIF":3.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease. 布雷克哌唑口服片剂是首款获准用于治疗阿尔茨海默病引起的痴呆症相关躁动症状的药物，对该药物进行了严格审查。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-29 DOI: 10.1080/14737175.2024.2407836

Kate Zhong, Jeffrey Cummings

{"title":"A critical review of brexpiprazole oral tablets as the first drug approved to treat agitation symptoms associated with dementia due to Alzheimer's disease.","authors":"Kate Zhong, Jeffrey Cummings","doi":"10.1080/14737175.2024.2407836","DOIUrl":"https://doi.org/10.1080/14737175.2024.2407836","url":null,"abstract":"Introduction: Agitation is a common and disruptive syndrome in dementia due to Alzheimer's disease (AD). Brexpiprazole was recently approved for this agitation of AD dementia and is the only therapy approved for this indication.Areas covered: The authors review the chemistry, pharmacokinetics, mechanism of action, and pharmacodynamics of brexpiprazole. Phase 2/3 and Phase 3 studies of brexpiprazole for the treatment of agitation in dementia due to AD are described. These studies demonstrated efficacy and safety for the 2 mg/d and 3 mg/d doses. Agitation reduction from baseline was significantly greater in the active treatment groups compared to the participants on placebo as measured by the Cohen-Mansfield Agitation Inventory, the primary outcome. Treatment benefit was demonstrated on the Clinician Global Impression - Severity, the key secondary outcome. Safety and tolerability were comparable in drug and placebo arms of the studies.Expert opinion: Approval by the Food and Drug Administration (FDA) of brexpiprazole for the treatment of agitation in dementia due to AD is an important milestone and regulatory precedent. This is the first approval for the treatment of any neuropsychiatric syndrome of AD. Brexpiprazole has a 'black box' warning for its use in psychosis caused by dementia due to an observed increase in mortality when using this class of antipsychotic agents in patients with dementia. Post-marketing surveillance will be key to understanding the safety profile of brexpiprazole. Brexpiprazole may be prioritized over the 'off label' use of other potential treatments for agitation.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-9"},"PeriodicalIF":3.4,"publicationDate":"2024-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An overview of the current and emerging treatment options for vestibular migraine. 前庭性偏头痛的现有和新兴治疗方案概览。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-26 DOI: 10.1080/14737175.2024.2405739

Elena P Calandre, Christine Bassila, Mahmoud Slim, Fernando Rico-Villademoros

{"title":"An overview of the current and emerging treatment options for vestibular migraine.","authors":"Elena P Calandre, Christine Bassila, Mahmoud Slim, Fernando Rico-Villademoros","doi":"10.1080/14737175.2024.2405739","DOIUrl":"https://doi.org/10.1080/14737175.2024.2405739","url":null,"abstract":"Introduction: Vestibular migraine is a relatively common syndrome characterized by the occurrence of vertigo and other vestibular symptoms, frequently -but not always- accompanied by migraine symptoms, such as headache, photophobia, and phonophobia.Areas covered: The authors review the acute or abortive treatment during an attack and prophylactic treatment of vestibular migraines, including pharmacological and non-pharmacological options.Expert opinion: Since its recognition as an independent clinical entity is recent, studies concerning its different treatment alternatives are still scarce, and the level of evidence of published studies is generally low. For acute treatment, although available data are conflicting, triptans are usually tried first. Neurostimulating devices can also be considered for acute treatment of vestibular migraine. Regarding the preventive treatment of vestibular migraine, based on the results of two randomized clinical trials and its pharmacological properties, flunarizine should be considered as the first treatment option. Second-line preventive treatments encompass propranolol, topiramate, venlafaxine, and valproic acid. Among non-pharmacological options, vestibular rehabilitation seems to be a sound prophylactic treatment option.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-23"},"PeriodicalIF":3.4,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344304","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intranasal zavegepant for the acute treatment of migraine. 用于偏头痛急性期治疗的zavegepant气雾剂。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-23 DOI: 10.1080/14737175.2024.2405741

Guy Greco, Teshamae Monteith

{"title":"Intranasal zavegepant for the acute treatment of migraine.","authors":"Guy Greco, Teshamae Monteith","doi":"10.1080/14737175.2024.2405741","DOIUrl":"https://doi.org/10.1080/14737175.2024.2405741","url":null,"abstract":"Introduction: Migraine is a highly prevalent chronic, inherited neurological condition of the brain which carries a significant level of disability. Despite advances, there is an unmet need for more effective therapies.Areas covered: Zavegepant nasal spray is a recent therapeutic option which acts as a calcitonin gene-related peptide receptor antagonist. The objective is to review the efficacy, safety, and additional results of the most recent trials investigating intranasal zavegepant for the acute treatment of migraine with or without aura. The authors searched PubMed using the keywords 'zavegepant,' 'Zavzpret,' 'migraine,' 'calcitonin gene-related peptide,' 'CGRP receptor antagonists.' This article covers Phase 1, Phase 2/3, and Phase 3 randomized, double-blind, placebo-controlled trials to evaluate the efficacy of intranasal zavegepant for treatment of acute migraine attacks.Expert opinion: Intranasal zavegepant is an efficacious, safe, and tolerable anti-migraine drug based on clinical trials and clinical experience. It is especially useful for patients who experience attacks of sudden onset, those with nausea or vomiting, or a high cardiovascular risk burden. Dysgeusia was common; future studies are needed to better characterize this adverse event. Head-to-head studies are lacking with other migraine-specific therapies; the decision to treat should be patient-centered, with attack-specific characteristics in mind.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-10"},"PeriodicalIF":3.4,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Behavioural Therapy for tic disorders: a comprehensive review of the literature. 治疗抽搐症的行为疗法：文献综述。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-22 DOI: 10.1080/14737175.2024.2405740

Simon Morand-Beaulieu, Natalia Szejko, Julian Fletcher, Tamara Pringsheim

{"title":"Behavioural Therapy for tic disorders: a comprehensive review of the literature.","authors":"Simon Morand-Beaulieu, Natalia Szejko, Julian Fletcher, Tamara Pringsheim","doi":"10.1080/14737175.2024.2405740","DOIUrl":"https://doi.org/10.1080/14737175.2024.2405740","url":null,"abstract":"Introduction: Behavioral therapies are recommended as a first-line intervention for Tourette syndrome and persistent motor or phonic tic disorder.Areas covered: In this review, the authors summarize randomized controlled trials on the comprehensive behavioral intervention for tics (CBIT), habit reversal therapy (HRT), and exposure and response prevention (ERP). Studies of face-to-face treatment, treatment by video conferencing, group treatment, and internet delivered treatment were assessed, as well as evidence of treatment predictors, modifiers, and mediators.Expert opinion: There is high-quality evidence for face-to-face one-on-one treatment with CBIT, and data suggesting that one-on-one treatment by videoconference provides similar benefit. Limited data on group treatment with CBIT/HRT suggests inferiority to individual treatment, while internet-based CBIT programs appear more beneficial than wait list or psychoeducation. There is one face-to-face one-on-one treatment comparison of ERP to HRT, suggesting equal benefit. Internet-based ERP with minimal therapist support appears effective, although effect sizes are small. One study using behavioral therapy with ERP or HRT found similar benefit to medical treatment with antipsychotics. Data on predictors, modifiers, and mediators of treatment efficacy are emerging. In summary, behavioral therapies are an important treatment modality for tic disorders. Furthermore, important efforts to improve treatment accessibility are underway.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":" ","pages":"1-11"},"PeriodicalIF":3.4,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Profiling aducanumab as a treatment option for alzheimer's disease: an overview of efficacy, safety and tolerability. 分析阿杜单抗作为阿尔茨海默病治疗方案的疗效、安全性和耐受性综述。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-18 DOI: 10.1080/14737175.2024.2402058

Shreeya Thussu,Aniketh Naidu,Sindhu Manivannan,George T Grossberg

{"title":"Profiling aducanumab as a treatment option for alzheimer's disease: an overview of efficacy, safety and tolerability.","authors":"Shreeya Thussu,Aniketh Naidu,Sindhu Manivannan,George T Grossberg","doi":"10.1080/14737175.2024.2402058","DOIUrl":"https://doi.org/10.1080/14737175.2024.2402058","url":null,"abstract":"INTRODUCTIONAlzheimer's disease is the most common form of dementia worldwide. Aducanumab, a monoclonal antibody targeting amyloid-beta, became the first disease-modifying treatment for mild cognitive impairment due to Alzheimer's disease (AD) and mild AD dementia and suggested that removing amyloid from the brain, especially in early AD, might make a difference in slowing cognitive decline.AREAS COVEREDIn this review, the authors outline aducanumab's clinical efficacy as shown through key clinical trials and discuss its approval by the Food and Drug Administration under the accelerated pathway, which sparked both hope and controversy. We also discuss the importance of amyloid-related imaging abnormalities as a major side effect of aducanumab and all subsequent monoclonal antibodies targeting amyloid-beta.EXPERT OPINIONAducanumab, became the first monoclonal antibody that provided at least partial support for the amyloid hypothesis by demonstrating slowed cognitive decline by removing amyloid from the brain, although full FDA approval now seems unlikely due to discontinuation of its development. Its introduction raised awareness of ARIA, highlighted the significant costs and need for informed consent in treatment, and emphasized the importance of long-term, diverse, and combination therapy data for future AD treatments targeting amyloid and tau.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":"402 1","pages":"1-9"},"PeriodicalIF":4.3,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142254178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine. Rimegepant 和 atogepant：为偏头痛治疗提供创新机会的新型药物。

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-12 DOI: 10.1080/14737175.2024.2401558

William David Wells-Gatnik,Lanfranco Pellesi,Paolo Martelletti

{"title":"Rimegepant and atogepant: novel drugs providing innovative opportunities in the management of migraine.","authors":"William David Wells-Gatnik,Lanfranco Pellesi,Paolo Martelletti","doi":"10.1080/14737175.2024.2401558","DOIUrl":"https://doi.org/10.1080/14737175.2024.2401558","url":null,"abstract":"INTRODUCTIONRimegepant and atogepant, two innovative oral medications for the treatment of migraine, are gaining prominence in the treatment of migraine. However, outside of specialist headache centers, these novel medications remain subjectively underutilized. While multiple rationales exist describing their underutilization, a leading factor is the complexity and clinical flexibility attributed to the individual members of the gepant medication class.AREAS COVEREDThis review provides a brief review of the current uses, common adverse events, and potential areas of future clinical innovation attributed to rimegepant and atogepant. A database search for the term 'Rimegepant OR Atogepant' was completed, yielding 240 individual results. Following multiple rounds of assessment that aimed to determine relevance of each individual result, 42 studies were included in the synthesis of this review.EXPERT OPINIONRimegepant and atogepant are exciting medications that demonstrate significant clinical innovation within the field of migraine therapy. While current indications are clear, data is lacking regarding the future expanded roles of these medications. Current areas of potential therapeutic innovation for rimegepant and atogepant include the pediatric population, in pregnancy and breastfeeding, in cluster headache and post-traumatic headache, and in patients that previously discontinued calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) therapy.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":"6 1","pages":"1-11"},"PeriodicalIF":4.3,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142205617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sacroiliac joint pain: what treatment and when. 骶髂关节疼痛：何时治疗？

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-11 DOI: 10.1080/14737175.2024.2400682

Federico Cocconi,Nicola Maffulli,Andreas Bell,Michael Kurt Memminger,Francesco Simeone,Filippo Migliorini

{"title":"Sacroiliac joint pain: what treatment and when.","authors":"Federico Cocconi,Nicola Maffulli,Andreas Bell,Michael Kurt Memminger,Francesco Simeone,Filippo Migliorini","doi":"10.1080/14737175.2024.2400682","DOIUrl":"https://doi.org/10.1080/14737175.2024.2400682","url":null,"abstract":"INTRODUCTIONSpinal and non-spinal pathologies can cause low back pain. Non-spinal sources of low back pain include the sacroiliac joint (SIJ) and the hip. SIJ pain can be treated either conservatively or surgically. Current strategies for managing sacroiliac joint pain are debated, and limited evidence exists.AREAS COVEREDThe present expert opinion updates current evidence on conservative and surgical modalities for SIJ pain.EXPERT OPINIONSurgical management for SIJ pain is effective. However, it exposes patients to surgery and, therefore, related complications. Conservative management may be implemented in patients with moderate SIJ pain, with less than six months of symptoms, or not eligible for surgery. Several noninvasive modalities are available, mostly centered on intra-articular injections. Corticosteroids, platelet-rich plasma, and stem cells have only midterm lasting effects, at most for nine months. Radiofrequency ablation is another methodology for pain relief. Both continuous and pulsatile radiofrequency ablation are associated with good outcomes. SIJ fusion can be performed using different techniques; however, a clear recommendation on the most appropriate modality for the management of SIJ pain is still debated.","PeriodicalId":12190,"journal":{"name":"Expert Review of Neurotherapeutics","volume":"15 1","pages":"1-8"},"PeriodicalIF":4.3,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142205598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

When is pharmacological intervention recommended for adults with social anxiety disorder? 何时建议对患有社交焦虑症的成年人进行药物干预？

IF 4.3 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-10 DOI: 10.1080/14737175.2024.2401556

Franklin R Schneier

引用次数: 0

Correction. 更正。

IF 3.4 2区医学

Expert Review of Neurotherapeutics Pub Date : 2024-09-08 DOI: 10.1080/14737175.2024.2398883

引用次数: 0